Pathogenetic mechanisms in gastric cancer

World Journal of Gastroenterology

Volumn 20, Issue 38, 2014, Pages 13804-13819

  Shi, Jing ^a   Qu, Yi Ping ^a   Hou, Peng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Epigenetic alterations; Gastric cancer; Genetic alterations; Risk factors; Signaling pathways

Indexed keywords

AZACITIDINE; BEVACIZUMAB; CAPECITABINE; CEDIRANIB; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2; EVEROLIMUS; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAPATINIB; MARIMASTAT; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTAGLANDIN E2; PROTEIN KINASE B; PROTEIN P53; RAMUCIRUMAB; RETINOBLASTOMA PROTEIN; RILOTUMUMAB; SORAFENIB; SUNITINIB; TRANSCRIPTION FACTOR RUNX3; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VORINOSTAT; ZEBULARINE; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CARCINOGENESIS; DNA METHYLATION; ENVIRONMENTAL FACTOR; GENE AMPLIFICATION; GENE DOSAGE; GENE MUTATION; HISTONE MODIFICATION; HUMAN; PATHOGENESIS; PRECANCER; PROMOTER REGION; RISK FACTOR; SIGNAL TRANSDUCTION; STOMACH CANCER; WNT SIGNALING PATHWAY; ANIMAL; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; METABOLISM; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; STOMACH NEOPLASMS;

ANIMALS; BIOMARKERS, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE-ENVIRONMENT INTERACTION; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84910011097     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i38.13804     Document Type: Article

References (236)

1. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol 2006; 12: 17-20 [PMID: 16440411]
2. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005; 241: 27-39 [PMID: 15621988]
3. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354-362 [PMID: 16489633]
4. Zou XM, Li YL, Wang H, Cui W, Li XL, Fu SB, Jiang HC. Gastric cancer cell lines induced by trichostatin A. World J Gastroenterol 2008; 14: 4810-4815 [PMID: 18720545]
5. Stelzner S, Emmrich P. The mixed type in Laurén's classification of gastric carcinoma. Histologic description and biologic behavior. Gen Diagn Pathol 1997; 143: 39-48 [PMID: 9269907]
6. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789 [PMID: 11556297 DOI: 10.1056/NEJMoa001999]
7. Kato M, Asaka M. Recent development of gastric cancer prevention. Jpn J Clin Oncol 2012; 42: 987-994 [PMID: 23018579 DOI: 10.1093/jjco/hys151]
8. Zabaleta J. Multifactorial etiology of gastric cancer. Methods Mol Biol 2012; 863: 411-435 [PMID: 22359309 DOI: 10.1007/978-1-61779-612-8-26]
9. Figueiredo C, Garcia-Gonzalez MA, Machado JC. Molecular pathogenesis of gastric cancer. Helicobacter 2013; 18 Suppl 1: 28-33 [PMID: 24011242 DOI: 10.1111/hel.12083]
10. Resende C, Ristimäki A, Machado JC. Genetic and epigenetic alteration in gastric carcinogenesis. Helicobacter 2010; 15 Suppl 1: 34-39 [PMID: 21054651 DOI: 10.1111/j.1523-5378.2010.00782.x]
11. Calcagno DQ, Gigek CO, Chen ES, Burbano RR, Smith Mde A. DNA and histone methylation in gastric carcinogenesis. World J Gastroenterol 2013; 19: 1182-1192 [PMID: 23482412 DOI: 10.3748/wjg.v19.i8.1182]
12. Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clin Chim Acta 2013; 424: 53-65 [PMID: 23669186 DOI: 10.1016/j.cca.2013.05.002]
13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]
14. Tsugane S, Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer 2007; 10: 75-83 [PMID: 17577615 DOI: 10.1007/s10120-007-0420-0]
15. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol 2009; 71: 127-164 [PMID: 19230702 DOI: 10.1016/j.critrevonc.2009.01.004]
16. Houghton J, Wang TC. Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology 2005; 128: 1567-1578 [PMID: 15887152]
17. Fock KM, Ang TL. Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. J Gastroenterol Hepatol 2010; 25: 479-486 [PMID: 20370726 DOI: 10.1111/j.1440-1746.2009.06188.x]
18. Compare D, Rocco A, Nardone G. Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci 2010; 14: 302-308 [PMID: 20496539]
19. Pandey R, Misra V, Misra SP, Dwivedi M, Kumar A, Tiwari BK. Helicobacter pylori and gastric cancer. Asian Pac J Cancer Prev 2010; 11: 583-588 [PMID: 21039020]
20. Correa P, Piazuelo MB, Camargo MC. The future of gastric cancer prevention. Gastric Cancer 2004; 7: 9-16 [PMID: 15052434 DOI: 10.1007/s10120-003-0265-0]
21. Augusto AC, Miguel F, Mendonc¸a S, Pedrazzoli J, Gurgueira SA. Oxidative stress expression status associated to Helicobacter pylori virulence in gastric diseases. Clin Biochem 2007; 40: 615-622 [PMID: 17466292 DOI: 10.1016/j.clinbiochem.2007.03.014]
22. Barros R, Freund JN, David L, Almeida R. Gastric intestinal metaplasia revisited: function and regulation of CDX2. Trends Mol Med 2012; 18: 555-563 [PMID: 22871898 DOI: 10.1016/j.molmed.2012.07.006]
23. Nakajima T, Yamashita S, Maekita T, Niwa T, Nakazawa K, Ushijima T. The presence of a methylation fingerprint of Helicobacter pylori infection in human gastric mucosae. Int J Cancer 2009; 124: 905-910 [PMID: 19035455 DOI: 10.1002/ijc.24018]
24. Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T, Ichinose M, Tatematsu M, Ushijima T. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res 2010; 70: 1430-1440 [PMID: 20124475 DOI: 10.1158/0008-5472.can-09-2755]
25. Shin CM, Kim N, Jung Y, Park JH, Kang GH, Kim JS, Jung HC, Song IS. Role of Helicobacter pylori infection in aberrant DNA methylation along multistep gastric carcinogenesis. Cancer Sci 2010; 101: 1337-1346 [PMID: 20345486 DOI: 10.1111/j.1349-7006.2010.01535.x]
26. Hur K, Niwa T, Toyoda T, Tsukamoto T, Tatematsu M, Yang HK, Ushijima T. Insufficient role of cell proliferation in aberrant DNA methylation induction and involvement of specific types of inflammation. Carcinogenesis 2011; 32: 35-41 [PMID: 20980348 DOI: 10.1093/carcin/bgq219]
27. Tsugane S. Salt, salted food intake, and risk of gastric cancer: epidemiologic evidence. Cancer Sci 2005; 96: 1-6 [PMID: 15649247 DOI: 10.1111/j.1349-7006.2005.00006.x]
28. Tatematsu M, Takahashi M, Fukushima S, Hananouchi M, Shirai T. Effects in rats of sodium chloride on experimental gastric cancers induced by N-methyl-N-nitro-N-nitrosoguanidine or 4-nitroquinoline-1-oxide. J Natl Cancer Inst 1975; 55: 101-106 [PMID: 808633]
29. Bilici M, Cayir K, Tekin SB, Gundogdu C, Albayrak A, Suleyman B, Ozogul B, Erdemci B, Suleyman H. Effect of mirtazapine on MNNG-induced gastric adenocarcinoma in rats. Asian Pac J Cancer Prev 2012; 13: 4897-4900 [PMID: 23244077]
30. Suzuki H, Iijima K, Scobie G, Fyfe V, McColl KE. Nitrate and nitrosative chemistry within Barrett's oesophagus during acid reflux. Gut 2005; 54: 1527-1535 [PMID: 16227357 DOI: 10.1136/gut.2005.066043]
31. Mitacek EJ, Brunnemann KD, Suttajit M, Caplan LS, Gagna CE, Bhothisuwan K, Siriamornpun S, Hummel CF, Ohshima H, Roy R, Martin N. Geographic distribution of liver and stomach cancers in Thailand in relation to estimated dietary intake of nitrate, nitrite, and nitrosodimethylamine. Nutr Cancer 2008; 60: 196-203 [PMID: 18444151 DOI: 10.1080/01635580701649636]
32. Liu C, Russell RM. Nutrition and gastric cancer risk: an update. Nutr Rev 2008; 66: 237-249 [PMID: 18454810 DOI: 10.1111/j.1753-4887.2008.00029.x]
33. Tsugane S, Sasazuki S, Kobayashi M, Sasaki S. Salt and salted food intake and subsequent risk of gastric cancer among middle-aged Japanese men and women. Br J Cancer 2004; 90: 128-134 [PMID: 14710219 DOI: 10.1038/sj.bjc.6601511]
34. Wang XQ, Terry PD, Yan H. Review of salt consumption and stomach cancer risk: epidemiological and biological evidence. World J Gastroenterol 2009; 15: 2204-2213 [PMID: 19437559]
35. Krejs GJ. Gastric cancer: epidemiology and risk factors. Dig Dis 2010; 28: 600-603 [PMID: 21088409 DOI: 10.1159/000320277]
36. Hou IC, Amarnani S, Chong MT, Bishayee A. Green tea and the risk of gastric cancer: epidemiological evidence. World J Gastroenterol 2013; 19: 3713-3722 [PMID: 23840110 DOI: 10.3748/wjg.v19.i24.3713]
37. Trédaniel J, Boffetta P, Buiatti E, Saracci R, Hirsch A. Tobacco smoking and gastric cancer: review and meta-analysis. Int J Cancer 1997; 72: 565-573 [PMID: 9259392]
38. Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. J Surg Oncol 2013; 107: 230-236 [PMID: 23129495 DOI: 10.1002/jso.23262]
39. Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol 2013; 23: 3-9 [PMID: 23207041 DOI: 10.1016/j.semradonc.2012.09.008]
40. Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JF. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995; 274: 474-477 [PMID: 7629956]
41. Crane SJ, Locke GR, Harmsen WS, Diehl NN, Zinsmeister AR, Melton LJ, Romero Y, Talley NJ. Subsite-specific risk factors for esophageal and gastric adenocarcinoma. Am J Gastroenterol 2007; 102: 1596-1602 [PMID: 17459024 DOI: 10.1111/j.1572-0241.2007.01234.x]
42. Bellini MF, Cadamuro AC, Succi M, Proenc¸a MA, Silva AE. Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol 2012; 2012: 891961 [PMID: 22919278 DOI: 10.1155/2012/891961]
43. Cheng XX, Wang ZC, Chen XY, Sun Y, Kong QY, Liu J, Li H. Correlation of Wnt-2 expression and beta-catenin intracellular accumulation in Chinese gastric cancers: relevance with tumour dissemination. Cancer Lett 2005; 223: 339-347 [PMID: 15896469 DOI: 10.1016/j.canlet.2004.11.013]
44. Cao HJ, Fang Y, Zhang X, Chen WJ, Zhou WP, Wang H, Wang LB, Wu JM. Tumor metastasis and the reciprocal regulation of heparanase gene expression by nuclear factor kappa B in human gastric carcinoma tissue. World J Gastroenterol 2005; 11: 903-907 [PMID: 15682491]
45. Yu HG, Ai YW, Yu LL, Zhou XD, Liu J, Li JH, Xu XM, Liu S, Chen J, Liu F, Qi YL, Deng Q, Cao J, Liu SQ, Luo HS, Yu JP. Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer 2008; 122: 433-443 [PMID: 17935137 DOI: 10.1002/ijc.23049]
46. Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A. TP53 and gastric carcinoma: a review. Hum Mutat 2003; 21: 258-270 [PMID: 12619111 DOI: 10.1002/humu.10180]
47. Souza RF. Molecular and biologic basis of upper gastrointestinal malignancy - esophageal carcinoma. Surg Oncol Clin N Am 2002; 11: 257-72, viii [PMID: 12424849]
48. Tamura G. Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol 2006; 12: 192-198 [PMID: 16482617]
49. Karaman A, Kabalar ME, Binici DN, Oztürk C, Pirim I. Genetic alterations in gastric precancerous lesions. Genet Couns 2010; 21: 439-450 [PMID: 21290973]
50. Warfel NA, El-Deiry WS. p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol 2013; 25: 52-58 [PMID: 23159848 DOI: 10.1097/CCO.0b013e32835b639e]
51. Kouraklis G, Katsoulis IE, Theocharis S, Tsourouflis G, Xipolitas N, Glinavou A, Sioka C, Kostakis A. Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma? Dig Dis Sci 2009; 54: 1015-1020 [PMID: 19058005 DOI: 10.1007/s10620-008-0464-y]
52. Michl P, Downward J. Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z Gastroenterol 2005; 43: 1133-1139 [PMID: 16220453 DOI: 10.1055/s-2005-858638]
53. Sukawa Y, Yamamoto H, Nosho K, Kunimoto H, Suzuki H, Adachi Y, Nakazawa M, Nobuoka T, Kawayama M, Mikami M, Matsuno T, Hasegawa T, Hirata K, Imai K, Shinomura Y. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer. World J Gastroenterol 2012; 18: 6577-6586 [PMID: 23236232 DOI: 10.3748/wjg.v18.i45.6577]
54. Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16: 121-130 [PMID: 22239433 DOI: 10.1517/147 28222.2011.644788]
55. Shi J, Yao D, Liu W, Wang N, Lv H, Zhang G, Ji M, Xu L, He N, Shi B, Hou P. Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer 2012; 12: 50 [PMID: 22292935 DOI: 10.1186/1471-2407-12-50]
56. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, Lim KH, Ong CK, Huang D, Chin SY, Tan IB, Ng CC, Yu W, Wu Y, Lee M, Wu J, Poh D, Wan WK, Rha SY, So J, Salto-Tellez M, Yeoh KG, Wong WK, Zhu YJ, Futreal PA, Pang B, Ruan Y, Hillmer AM, Bertrand D, Nagarajan N, Rozen S, Teh BT, Tan P. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012; 44: 570-574 [PMID: 22484628 DOI: 10.1038/ng.2246]
57. Corso G, Velho S, Paredes J, Pedrazzani C, Martins D, Milanezi F, Pascale V, Vindigni C, Pinheiro H, Leite M, Marrelli D, Sousa S, Carneiro F, Oliveira C, Roviello F, Seruca R. Oncogenic mutations in gastric cancer with microsatellite instability. Eur J Cancer 2011; 47: 443-451 [PMID: 20937558 DOI: 10.1016/j.ejca.2010.09.008]
58. Lee J, van Hummelen P, Go C, Palescandolo E, Jang J, Park HY, Kang SY, Park JO, Kang WK, MacConaill L, Kim KM. High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS One 2012; 7: e38892 [PMID: 22723903 DOI: 10.1371/journal.pone.0038892]
59. Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer 2010; 10: 59-64 [PMID: 20029424 DOI: 10.1038/nrc2771]
60. Peng DF, Sugihara H, Mukaisho K, Tsubosa Y, Hattori T. Alterations of chromosomal copy number during progression of diffuse-type gastric carcinomas: metaphase- and array-based comparative genomic hybridization analyses of multiple samples from individual tumours. J Pathol 2003; 201: 439-450 [PMID: 14595756 DOI: 10.1002/path.1459]
61. Buffart TE, van Grieken NC, Tijssen M, Coffa J, Ylstra B, Grabsch HI, van de Velde CJ, Carvalho B, Meijer GA. High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch 2009; 455: 213-223 [PMID: 19697059 DOI: 10.1007/s00428-009-0814-y]
62. Zhang D, Wang Z, Luo Y, Xu Y, Liu Y, Yang W, Zhang X. Analysis of DNA copy number aberrations by multiple ligation-dependent probe amplification on 50 intestinal type gastric cancers. J Surg Oncol 2011; 103: 124-132 [PMID: 21259245 DOI: 10.1002/jso.21792]
63. Schwab M. Amplification of oncogenes in human cancer cells. Bioessays 1998; 20: 473-479 [PMID: 9699459 DOI: 10.100 2/(sici)1521-1878(199806)20:6〈473::aid-bies5〉3.0.co;2-n]
64. Albertson DG. Gene amplification in cancer. Trends Genet 2006; 22: 447-455 [PMID: 16787682 DOI: 10.1016/j.tig.2006.06.007]
65. Guo CY, Xu XF, Wu JY, Liu SF. PCR-SSCP-DNA sequencing method in detecting PTEN gene mutation and its significance in human gastric cancer. World J Gastroenterol 2008; 14: 3804-3811 [PMID: 18609703]
66. Wen YG, Wang Q, Zhou CZ, Qiu GQ, Peng ZH, Tang HM. Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway. Oncol Rep 2010; 24: 89-95 [PMID: 20514448]
67. Ocaña A, Pandiella A. Targeting HER receptors in cancer. Curr Pharm Des 2013; 19: 808-817 [PMID: 22973952]
68. Zhang XL, Yang YS, Xu DP, Qu JH, Guo MZ, Gong Y, Huang J. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 2009; 33: 2112-2118 [PMID: 19636613 DOI: 10.1007/s00268-009-0142-z]
69. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010; 1802: 396-405 [PMID: 20079433 DOI: 10.1016/j.bbadis.2009.12.009]
70. Young A, Lyons J, Miller AL, Phan VT, Alarcón IR, McCormick F. Ras signaling and therapies. Adv Cancer Res 2009; 102: 1-17 [PMID: 19595305 DOI: 10.1016/s0065-230x(09)02001-6]
71. Lee SH, Lee JW, Soung YH, Kim HS, Park WS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ, Nam SW, Kim SH, Lee JY, Yoo NJ. BRAF and KRAS mutations in stomach cancer. Oncogene 2003; 22: 6942-6945 [PMID: 14534542 DOI: 10.1038/sj.onc.1206749]
72. Yoo J, Park SY, Robinson RA, Kang SJ, Ahn WS, Kang CS. ras Gene mutations and expression of Ras signal transduction mediators in gastric adenocarcinomas. Arch Pathol Lab Med 2002; 126: 1096-1100 [PMID: 12204060 DOI: 10.1043/0003-9985(2002)126〈1096:rgmaeo〉2.0.co;2]
73. Chen HC, Chen HJ, Khan MA, Rao ZZ, Wan XX, Tan B, Zhang DZ. Genetic mutations of p53 and k-ras in gastric carcinoma patients from Hunan, China. Tumour Biol 2011; 32: 367-373 [PMID: 21080251 DOI: 10.1007/s13277-010-0129-2]
74. Liang B, Wang S, Zhu XG, Yu YX, Cui ZR, Yu YZ. Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer. World J Gastroenterol 2005;11: 623-8 [PMID: 15655810]
75. Shi J, Zhang G, Yao D, Liu W, Wang N, Ji M, He N, Shi B, Hou P. Prognostic significance of aberrant gene methylation in gastric cancer. Am J Cancer Res 2012; 2: 116-129 [PMID: 22206050]
76. Yao D, Shi J, Shi B, Wang N, Liu W, Zhang G, Ji M, Xu L, He N, Hou P. Quantitative assessment of gene methylation and their impact on clinical outcome in gastric cancer. Clin Chim Acta 2012; 413: 787-794 [PMID: 22285775 DOI: 10.1016/j.cca.2012.01.013]
77. Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, Zhu RM, Li GL, Xia XY, Wei XW, Ji HZ, Lu H, Gao Y, Gao WM, Chen LB. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol 2008; 14: 3074-3080 [PMID: 18494062]
78. Endoh M, Tamura G, Honda T, Homma N, Terashima M, Nishizuka S, Motoyama T. RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br J Cancer 2005; 93: 1395-1399 [PMID: 16265349 DOI: 10.1038/sj.bjc.6602854]
79. Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baier K, Pfeifer GP. The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol 2005; 20: 645-663 [PMID: 15736067]
80. Alvarado D, Klein DE, Lemmon MA. ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor. Nature 2009; 461: 287-291 [PMID: 19718021 DOI: 10.1038/nature08297]
81. Slesak B, Harlozinska A, Porebska I, Bojarowski T, Lapinska J, Rzeszutko M, Wojnar A. Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis. Anticancer Res 1998; 18: 2727-2732 [PMID: 9703936]
82. Lee JW, Soung YH, Kim SY, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH. ERBB2 kinase domain mutation in a gastric cancer metastasis. APMIS 2005; 113: 683-687 [PMID: 16309427 DOI: 10.1111/j.1600-0463.2005.apm-284.x]
83. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16: 273-278 [PMID: 15668283 DOI: 10.1093/annonc/mdi064]
84. de Mello RA, Marques AM, Araújo A. HER2 therapies and gastric cancer: a step forward. World J Gastroenterol 2013; 19: 6165-6169 [PMID: 24115812 DOI: 10.3748/wjg.v19.i37.6165]
85. Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, da Costa WL, Soares FA. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 2011; 29: 3030-3036 [PMID: 21709195 DOI: 10.1200/jco.2010.33.6313]
86. Shi J, Yao D, Liu W, Wang N, Lv H, He N, Shi B, Hou P, Ji M. Frequent gene amplification predicts poor prognosis in gastric cancer. Int J Mol Sci 2012; 13: 4714-4726 [PMID: 22606006 DOI: 10.3390/ijms13044714]
87. Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y, Mori M. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res 2011; 17: 2725-2733 [PMID: 21220473 DOI: 10.1158/1078-0432.ccr-10-2132]
88. Kogo R, Mimori K, Tanaka F, Komune S, Mori M. Clinical significance of miR-146a in gastric cancer cases. Clin Cancer Res 2011; 17: 4277-4284 [PMID: 21632853 DOI: 10.1158/1078-0432.ccr-10-2866]
89. Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol 2012; 4: [PMID: 22438566 DOI: 10.1101/cshperspect.a008052]
90. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell 2012; 149: 1192-1205 [PMID: 22682243 DOI: 10.1016/j.cell.2012.05.012]
91. Zhang H, Xue Y. Wnt pathway is involved in advanced gastric carcinoma. Hepatogastroenterology 2008; 55: 1126-1130 [PMID: 18705344]
92. Pan KF, Liu WG, Zhang L, You WC, Lu YY. Mutations in components of the Wnt signaling pathway in gastric cancer. World J Gastroenterol 2008; 14: 1570-1574 [PMID: 18330950]
93. Kurayoshi M, Oue N, Yamamoto H, Kishida M, Inoue A, Asahara T, Yasui W, Kikuchi A. Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res 2006; 66: 10439-10448 [PMID: 17079465 DOI: 10.1158/0008-5472.can-06-2359]
94. Gencer S, Şen G, Doʇusoy G, Belli AK, Paksoy M, Yaziciog˚lu MB. β-Catenin-independent noncanonical Wnt pathway might be induced in gastric cancers. Turk J Gastroenterol 2010; 21: 224-230 [PMID: 20931424]
95. Perchiniak EM, Groden J. Mechanisms Regulating Microtubule Binding, DNA Replication, and Apoptosis are Controlled by the Intestinal Tumor Suppressor APC. Curr Colorectal Cancer Rep 2011; 7: 145-151 [PMID: 23308069 DOI: 10.1007/s11888-011-0088-z]
96. Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, Gaspar C, van Es JH, Breukel C, Wiegant J, Giles RH, Clevers H. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 2001; 3: 433-438 [PMID: 11283620 DOI: 10.1038/35070129]
97. Park WS, Oh RR, Park JY, Lee SH, Shin MS, Kim YS, Kim SY, Lee HK, Kim PJ, Oh ST, Yoo NJ, Lee JY. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res 1999; 59: 4257-4260 [PMID: 10485468]
98. Lee JH, Abraham SC, Kim HS, Nam JH, Choi C, Lee MC, Park CS, Juhng SW, Rashid A, Hamilton SR, Wu TT. Inverse relationship between APC gene mutation in gastric adenomas and development of adenocarcinoma. Am J Pathol 2002; 161: 611-618 [PMID: 12163385 DOI: 10.1016/s0002-9440(10)64216-2]
99. Horii A, Nakatsuru S, Miyoshi Y, Ichii S, Nagase H, Kato Y, Yanagisawa A, Nakamura Y. The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. Cancer Res 1992; 52: 3231-3233 [PMID: 1317264]
100. van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci 2008; 65: 3756-3788 [PMID: 18726070 DOI: 10.1007/s00018-008-8281-1]
101. Leckband D, Sivasankar S. Mechanism of homophilic cadherin adhesion. Curr Opin Cell Biol 2000; 12: 587-592 [PMID: 10978894]
102. Corso G, Marrelli D, Roviello F. Familial gastric cancer and germline mutations of E-cadherin. Ann Ital Chir 2012; 83: 177-182 [PMID: 22595728]
103. Corso G, Seruca R, Roviello F. Gastric cancer carcinogenesis and tumor progression. Ann Ital Chir 2012; 83: 172-176 [PMID: 22595727]
104. Carneiro P, Fernandes MS, Figueiredo J, Caldeira J, Carvalho J, Pinheiro H, Leite M, Melo S, Oliveira P, Simões-Correia J, Oliveira MJ, Carneiro F, Figueiredo C, Paredes J, Oliveira C, Seruca R. E-cadherin dysfunction in gastric cancer - cellular consequences, clinical applications and open questions. FEBS Lett 2012; 586: 2981-2989 [PMID: 22841718 DOI: 10.1016/j.febslet.2012.07.045]
105. Leal M, Lima E, Silva P, Assumpc¸ão P, Calcagno D, Payão S, Burbano RR, Smith M. Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from Northern Brazil. World J Gastroenterol 2007; 13: 2568-2574 [PMID: 17552003]
106. Grady WM, Willis J, Guilford PJ, Dunbier AK, Toro TT, Lynch H, Wiesner G, Ferguson K, Eng C, Park JG, Kim SJ, Markowitz S. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 2000; 26: 16-17 [PMID: 10973239 DOI: 10.1038/79120]
107. Taketo MM. Wnt signaling and gastrointestinal tumorigenesis in mouse models. Oncogene 2006; 25: 7522-7530 [PMID: 17143296 DOI: 10.1038/sj.onc.1210058]
108. Kang GH, Lee S, Cho NY, Gandamihardja T, Long TI, Weisenberger DJ, Campan M, Laird PW. DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest 2008; 88: 161-170 [PMID: 18158559 DOI: 10.1038/labinvest.3700707]
109. Nojima M, Suzuki H, Toyota M, Watanabe Y, Maruyama R, Sasaki S, Sasaki Y, Mita H, Nishikawa N, Yamaguchi K, Hirata K, Itoh F, Tokino T, Mori M, Imai K, Shinomura Y. Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene 2007; 26: 4699-4713 [PMID: 17297461 DOI: 10.1038/sj.onc.1210259]
110. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009; 8: 33-40 [PMID: 19116625 DOI: 10.1038/nrd2781]
111. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-466 [PMID: 15329734 DOI: 10.1038/nature02924]
112. Thanos D, Maniatis T. NF-kappa B: a lesson in family values. Cell 1995; 80: 529-532 [PMID: 7867060]
113. Nelson DE, Ihekwaba AE, Elliott M, Johnson JR, Gibney CA, Foreman BE, Nelson G, See V, Horton CA, Spiller DG, Edwards SW, McDowell HP, Unitt JF, Sullivan E, Grimley R, Benson N, Broomhead D, Kell DB, White MR. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science 2004; 306: 704-708 [PMID: 15499023 DOI: 10.1126/science.1099962]
114. Xiao G, Rabson AB, Young W, Qing G, Qu Z. Alternative pathways of NF-kappaB activation: a double-edged sword in health and disease. Cytokine Growth Factor Rev 2006; 17: 281-293 [PMID: 16793322 DOI: 10.1016/j.cytogfr.2006.04.005]
115. Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H, Nakamura K, Yamanaka T, Uchiyama A, Tanaka M, Katano M. Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 2001; 7: 4136-4142 [PMID: 11751513]
116. Yamanaka N, Sasaki N, Tasaki A, Nakashima H, Kubo M, Morisaki T, Noshiro H, Yao T, Tsuneyoshi M, Tanaka M, Katano M. Nuclear factor-kappaB p65 is a prognostic indicator in gastric carcinoma. Anticancer Res 2004; 24: 1071-1075 [PMID: 15154625]
117. Roberts AB. The ever-increasing complexity of TGF-beta signaling. Cytokine Growth Factor Rev 2002; 13: 3-5 [PMID: 11750874]
118. Shi Y, Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700 [PMID: 12809600]
119. Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J, Sung JJ. Dysregulation of cellular signaling in gastric cancer. Cancer Lett 2010; 295: 144-153 [PMID: 20488613 DOI: 10.1016/j.canlet.2010.04.025]
120. Guo W, Dong Z, Guo Y, Kuang G, Yang Z, Shan B. Concordant repression and aberrant methylation of transforming growth factor-beta signaling pathway genes occurs early in gastric cardia adenocarcinoma. Mol Biol Rep 2012; 39: 9453-9462 [PMID: 22722999 DOI: 10.1007/s11033-012-1810-x]
121. Lai KW, Koh KX, Loh M, Tada K, Subramaniam MM, Lim XY, Vaithilingam A, Salto-Tellez M, Iacopetta B, Ito Y, Soong R. MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer 2010; 46: 1456-1463 [PMID: 20176475 DOI: 10.1016/j.ejca.2010.01.036]
122. Lu XX, Yu JL, Ying LS, Han J, Wang S, Yu QM, Wang XB, Fang XH, Ling ZQ. Stepwise cumulation of RUNX3 methylation mediated by Helicobacter pylori infection contributes to gastric carcinoma progression. Cancer 2012; 118: 5507-5517 [PMID: 22576578 DOI: 10.1002/cncr.27604]
123. Lee SH, Kim J, Kim WH, Lee YM. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells. Oncogene 2009; 28: 184-194 [PMID: 18850007 DOI: 10.1038/onc.2008.377]
124. Tan SH, Ida H, Lau QC, Goh BC, Chieng WS, Loh M, Ito Y. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep 2007; 18: 1225-1230 [PMID: 17914577]
125. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18: 7908-7916 [PMID: 10630643 DOI: 10.1038/sj.onc.1203286]
126. Xue YW, Zhang QF, Zhu ZB, Wang Q, Fu SB. Expression of cyclooxygenase-2 and clinicopathologic features in human gastric adenocarcinoma. World J Gastroenterol 2003; 9: 250-253 [PMID: 12532441]
127. Shi H, Xu JM, Hu NZ, Xie HJ. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol 2003; 9: 1421-1426 [PMID: 12854133]
128. Oshima H, Oguma K, Du YC, Oshima M. Prostaglandin E2, Wnt, and BMP in gastric tumor mouse models. Cancer Sci 2009; 100: 1779-1785 [PMID: 19622104 DOI: 10.1111/j.1349-7006.2009.01258.x]
129. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, Ikeda T, Fueki M, Ueno A, Oh S, Kudo I. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000; 275: 32783-32792 [PMID: 10869354 DOI: 10.1074/jbc.M003505200]
130. Gross ND, Boyle JO, Morrow JD, Williams MK, Moskowitz CS, Subbaramaiah K, Dannenberg AJ, Duffield-Lillico AJ. Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin Cancer Res 2005; 11: 6087-6093 [PMID: 16115954 DOI: 10.1158/1078-0432.ccr-05-0733]
131. Huang RY, Chen GG. Cigarette smoking, cyclooxygenase-2 pathway and cancer. Biochim Biophys Acta 2011; 1815: 158-169 [PMID: 21147199 DOI: 10.1016/j.bbcan.2010.11.005]
132. Cito L, Pentimalli F, Forte I, Mattioli E, Giordano A. Rb family proteins in gastric cancer (review). Oncol Rep 2010; 24: 1411-1418 [PMID: 21042734]
133. Tian Y, Wan H, Tan G. Cell cycle-related kinase in carcinogenesis. Oncol Lett 2012; 4: 601-606 [PMID: 23205069 DOI: 10.3892/ol.2012.828]
134. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J. Retinoblastoma-protein-dependent cellcycle inhibition by the tumour suppressor p16. Nature 1995; 375: 503-506 [PMID: 7777060 DOI: 10.1038/375503a0]
135. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330 [PMID: 7736585]
136. He XS, Su Q, Chen ZC, He XT, Long ZF, Ling H, Zhang LR. Expression, deletion [was deleton] and mutation of p16 gene in human gastric cancer. World J Gastroenterol 2001; 7: 515-521 [PMID: 11819820]
137. Mitsuno M, Kitajima Y, Ide T, Ohtaka K, Tanaka M, Satoh S, Miyazaki K. Aberrant methylation of p16 predicts candidates for 5-fluorouracil-based adjuvant therapy in gastric cancer patients. J Gastroenterol 2007; 42: 866-873 [PMID: 18008030 DOI: 10.1007/s00535-007-2113-1]
138. Ikoma H, Ichikawa D, Koike H, Ikoma D, Tani N, Okamoto K, Ochiai T, Ueda Y, Otsuji E, Yamagishi H. Correlation between serum DNA methylation and prognosis in gastric cancer patients. Anticancer Res 2006; 26: 2313-2316 [PMID: 16821608]
139. Lee TL, Leung WK, Chan MW, Ng EK, Tong JH, Lo KW, Chung SC, Sung JJ, To KF. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 2002; 8: 1761-1766 [PMID: 12060614]
140. Hudler P. Genetic aspects of gastric cancer instability. ScientificWorldJournal 2012; 2012: 761909 [PMID: 22606061 DOI: 10.1100/2012/761909]
141. Buffart TE, Louw M, van Grieken NC, Tijssen M, Carvalho B, Ylstra B, Grabsch H, Mulder CJ, van de Velde CJ, van der Merwe SW, Meijer GA. Gastric cancers of Western European and African patients show different patterns of genomic instability. BMC Med Genomics 2011; 4: 7 [PMID: 21226972 DOI: 10.1186/1755-8794-4-7]
142. Tao J, Deng NT, Ramnarayanan K, Huang B, Oh HK, Leong SH, Lim SS, Tan IB, Ooi CH, Wu J, Lee M, Zhang S, Rha SY, Chung HC, Smoot DT, Ashktorab H, Kon OL, Cacheux V, Yap C, Palanisamy N, Tan P. CD44-SLC1A2 gene fusions in gastric cancer. Sci Transl Med 2011; 3: 77ra30 [PMID: 21471434 DOI: 10.1126/scitranslmed.3001423]
143. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692 [PMID: 17320506 DOI: 10.1016/j.cell.2007.01.029]
144. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009; 8: 1409-1420 [PMID: 19509247 DOI: 10.1158/1535-7163.mct-08-0860]
145. Esteller M. DNA methylation and cancer therapy: new developments and expectations. Curr Opin Oncol 2005; 17: 55-60 [PMID: 15608514]
146. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838 [PMID: 15944708 DOI: 10.1038/nature03702]
147. Luo H, Zhang H, Zhang Z, Zhang X, Ning B, Guo J, Nie N, Liu B, Wu X. Down-regulated miR-9 and miR-433 in human gastric carcinoma. J Exp Clin Cancer Res 2009; 28: 82 [PMID: 19531230 DOI: 10.1186/1756-9966-28-82]
148. Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet 2012; 81: 303-311 [PMID: 22082348 DOI: 10.1111/j.1399-0004.2011.01809.x]
149. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31: 27-36 [PMID: 19752007 DOI: 10.1093/carcin/bgp220]
150. Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 2008; 15: 1968-1976 [PMID: 18470569 DOI: 10.1245/s10434-008-9927-9]
151. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/s0140-6736(10)61121-x]
152. Park SC, Chun HJ. Chemotherapy for advanced gastric cancer: review and update of current practices. Gut Liver 2013; 7: 385-393 [PMID: 23898376 DOI: 10.5009/gnl.2013.7.4.385]
153. Maehara Y, Kabashima A, Koga T, Tokunaga E, Takeuchi H, Kakeji Y, Sugimachi K. Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery 2000; 128: 408-416 [PMID: 10965312 DOI: 10.1067/msy.2000.107265]
154. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, Noguchi Y. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett 2000; 153: 7-12 [PMID: 10779624]
155. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968-3976 [PMID: 21844504 DOI: 10.1200/jco.2011.36.2236]
156. Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, Cheng Y, Wang Z, Zheng L, Tao M, Zhu X, Ji D, Liu X, Yu H. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol 2013; 31: 3219-3225 [PMID: 23918952 DOI: 10.1200/jco.2013.48.8585]
157. Liu L, Wu N, Li J. Novel targeted agents for gastric cancer. J Hematol Oncol 2012; 5: 31 [PMID: 22709792 DOI: 10.1186/1756-8722-5-31]
158. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 490-499 [PMID: 23594786 DOI: 10.1016/s1470-2045(13)70102-5]
159. Gadgeel SM, Lew DL, Synold TW, LoRusso P, Chung V, Christensen SD, Smith DC, Kingsbury L, Hoering A, Kurzrock R. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemother Pharmacol 2013; 72: 1089-1096 [PMID: 24057042 DOI: 10.1007/s00280-013-2297-4]
160. Iqbal S, Goldman B, Fenoglio-Preiser CM, Lenz HJ, Zhang W, Danenberg KD, Shibata SI, Blanke CD. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 2011; 22: 2610-2615 [PMID: 21415234 DOI: 10.1093/annonc/mdr021]
161. Wong H, Yau T. Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? Oncologist 2012; 17: 346-358 [PMID: 22334453 DOI: 10.1634/theoncologist.2011-0311]
162. Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Cutsem E. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 2013; 31: 3935-3943 [PMID: 24043745 DOI: 10.1200/jco.2012.48.3552]
163. Lim T, Lee J, Lee DJ, Lee HY, Han B, Baek KK, Ahn HK, Lee SJ, Park SH, Park JO, Park YS, Lim HY, Kim KM, Kang WK. Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Cancer Chemother Pharmacol 2011; 68: 255-262 [PMID: 21526353 DOI: 10.1007/s00280-011-1653-5]
164. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M, Fielding JW. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002; 86: 1864-1870 [PMID: 12085177 DOI: 10.1038/sj.bjc.6600310]
165. Ku GY, Ilson DH, Schwartz LH, Capanu M, O'Reilly E, Shah MA, Kelsen DP, Schwartz GK. Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother Pharmacol 2008; 62: 875-880 [PMID: 18270704 DOI: 10.1007/s00280-008-0677-y]
166. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980; 20: 85-93 [PMID: 6156004]
167. Kuendgen A, Lübbert M. Current status of epigenetic treatment in myelodysplastic syndromes. Ann Hematol 2008; 87: 601-611 [PMID: 18392623 DOI: 10.1007/s00277-008-0477-9]
168. Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 2009; 15: 3918-3926 [PMID: 19509169 DOI: 10.1158/1078-0432.ccr-08-2788]
169. Weiss AJ, Metter GE, Nealon TF, Keanan JP, Ramirez G, Swaiminathan A, Fletcher WS, Moss SE, Manthei RW. Phase II study of 5-azacytidine in solid tumors. Cancer Treat Rep 1977; 61: 55-58 [PMID: 67894]
170. Yoo CB, Jeong S, Egger G, Liang G, Phiasivongsa P, Tang C, Redkar S, Jones PA. Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 2007; 67: 6400-6408 [PMID: 17616700 DOI: 10.1158/0008-5472.can-07-0251]
171. Chuang JC, Warner SL, Vollmer D, Vankayalapati H, Redkar S, Bearss DJ, Qiu X, Yoo CB, Jones PA. S110, a 5-Aza-2′ -deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther 2010; 9: 1443-1450 [PMID: 20442312 DOI: 10.1158/1535-7163.mct-09-1048]
172. Yang CS, Wang X, Lu G, Picinich SC. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 2009; 9: 429-439 [PMID: 19472429 DOI: 10.1038/nrc2641]
173. Lee WJ, Shim JY, Zhu BT. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol Pharmacol 2005; 68: 1018-1030 [PMID: 16037419 DOI: 10.1124/mol.104.008367]
174. Cornacchia E, Golbus J, Maybaum J, Strahler J, Hanash S, Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 1988; 140: 2197-2200 [PMID: 3258330]
175. Park JH, Jung Y, Kim TY, Kim SG, Jong HS, Lee JW, Kim DK, Lee JS, Kim NK, Kim TY, Bang YJ. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res 2004; 10: 5271-5281 [PMID: 15297431 DOI: 10.1158/1078-0432.ccr-03-0709]
176. Duvic M, Vu J. Vorinostat in cutaneous T-cell lymphoma. Drugs Today (Barc) 2007; 43: 585-599 [PMID: 17940636 DOI: 10.1358/dot.2007.43.9.1112980]
177. Claerhout S, Lim JY, Choi W, Park YY, Kim K, Kim SB, Lee JS, Mills GB, Cho JY. Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PLoS One 2011; 6: e24662 [PMID: 21931799 DOI: 10.1371/journal.pone.0024662]
178. Yoo C, Ryu MH, Na YS, Ryoo BY, Lee CW, Maeng J, Kim SY, Koo DH, Park I, Kang YK. Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer. Invest New Drugs 2014; 32: 271-278 [PMID: 23712440 DOI: 10.1007/s10637-013-9983-2]
179. Kingsmore SF, Saunders CJ. Deep sequencing of patient genomes for disease diagnosis: when will it become routine? Sci Transl Med 2011; 3: 87ps23 [PMID: 21677196 DOI: 10.1126/scitranslmed.3002695]
180. Cooke S, Campbell P. Circulating DNA and next-generation sequencing. Recent Results Cancer Res 2012; 195: 143-149 [PMID: 22527501 DOI: 10.1007/978-3-642-28160-0-12]
181. Shi Y, Zhou Y. The role of surgery in the treatment of gastric cancer. J Surg Oncol 2010; 101: 687-692 [PMID: 20512944 DOI: 10.1002/jso.21455]
182. Lee HK, Lee HS, Yang HK, Kim WH, Lee KU, Choe KJ, Kim JP. Prognostic significance of Bcl-2 and p53 expression in gastric cancer. Int J Colorectal Dis 2003; 18: 518-525 [PMID: 12811476 DOI: 10.1007/s00384-003-0491-2]
183. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE. E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392: 402-405 [PMID: 9537325 DOI: 10.1038/32918]
184. Corso G, Carvalho J, Marrelli D, Vindigni C, Carvalho B, Seruca R, Roviello F, Oliveira C. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol 2013; 31: 868-875 [PMID: 23341533 DOI: 10.1200/jco.2012.44.4612]
185. Li JH, Shi XZ, Lü S, Liu M, Cui WM, Liu LN, Jiang J, Xu GW. HMLH1 gene mutation in gastric cancer patients and their kindred. World J Gastroenterol 2005; 11: 3144-3146 [PMID: 15918206]
186. Günther T, Schneider-Stock R, Pross M, Manger T, Malfertheiner P, Lippert H, Roessner A. Alterations of the p16/MTS1-tumor suppressor gene in gastric cancer. Pathol Res Pract 1998; 194: 809-813 [PMID: 9894245 DOI: 10.1016/s0344-0338(98)80082-4]
187. Wu MS, Shun CT, Sheu JC, Wang HP, Wang JT, Lee WJ, Chen CJ, Wang TH, Lin JT. Overexpression of mutant p53 and c-erbB-2 proteins and mutations of the p15 and p16 genes in human gastric carcinoma: with respect to histological subtypes and stages. J Gastroenterol Hepatol 1998; 13: 305-310 [PMID: 9570245]
188. Tokumaru Y, Nomoto S, Jerónimo C, Henrique R, Harden S, Trink B, Sidransky D. Biallelic inactivation of the RIZ1 gene in human gastric cancer. Oncogene 2003; 22: 6954-6958 [PMID: 14534544 DOI: 10.1038/sj.onc.1206403]
189. Piao Z, Fang W, Malkhosyan S, Kim H, Horii A, Perucho M, Huang S. Frequent frameshift mutations of RIZ in sporadic gastrointestinal and endometrial carcinomas with microsatellite instability. Cancer Res 2000; 60: 4701-4704 [PMID: 10987271]
190. Pan KF, Lu YY, Liu WG, Zhang L, You WC. Detection of frameshift mutations of RIZ in gastric cancers with microsatellite instability. World J Gastroenterol 2004; 10: 2719-2722 [PMID: 15309726]
191. Menoyo A, Alazzouzi H, Espín E, Armengol M, Yamamoto H, Schwartz S. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res 2001; 61: 7727-7730 [PMID: 11691784]
192. Ohmiya N, Matsumoto S, Yamamoto H, Baranovskaya S, Malkhosyan SR, Perucho M. Germline and somatic mutations in hMSH6 and hMSH3 in gastrointestinal cancers of the microsatellite mutator phenotype. Gene 2001; 272: 301-313 [PMID: 11470537]
193. Tate G, Suzuki T, Nemoto H, Kishimoto K, Hibi K, Mitsuya T. Allelic loss of the PTEN gene and mutation of the TP53 gene in choriocarcinoma arising from gastric adenocarcinoma: analysis of loss of heterozygosity in two male patients with extragonadal choriocarcinoma. Cancer Genet Cytogenet 2009; 193: 104-108 [PMID: 19665071 DOI: 10.1016/j.cancergencyto.2009.04.005]
194. Oki E, Kakeji Y, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, Yamamoto M, Ikebe M, Maehara Y. Impact of loss of heterozygosity of encoding phosphate and tensin homolog on the prognosis of gastric cancer. J Gastroenterol Hepatol 2006; 21: 814-818 [PMID: 16704528 DOI: 10.1111/j.1440-1746.2005.04028.x]
195. Ayhan A, Yasui W, Yokozaki H, Seto M, Ueda R, Tahara E. Loss of heterozygosity at the bcl-2 gene locus and expression of bcl-2 in human gastric and colorectal carcinomas. Jpn J Cancer Res 1994; 85: 584-591 [PMID: 8063611]
196. Candusso ME, Luinetti O, Villani L, Alberizzi P, Klersy C, Fiocca R, Ranzani GN, Solcia E. Loss of heterozygosity at 18q21 region in gastric cancer involves a number of cancer-related genes and correlates with stage and histology, but lacks independent prognostic value. J Pathol 2002; 197: 44-50 [PMID: 12081203 DOI: 10.1002/path.1105]
197. Lee KE, Lee HJ, Kim YH, Yu HJ, Yang HK, Kim WH, Lee KU, Choe KJ, Kim JP. Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol 2003; 33: 173-179 [PMID: 12810831]
198. Ouatas T, Salerno M, Palmieri D, Steeg PS. Basic and translational advances in cancer metastasis: Nm23. J Bioenerg Biomembr 2003; 35: 73-79 [PMID: 12848344]
199. Mönig SP, Nolden B, Lübke T, Pohl A, Grass G, Schneider PM, Dienes HP, Hölscher AH, Baldus SE. Clinical significance of nm23 gene expression in gastric cancer. Anticancer Res 2007; 27: 3029-3033 [PMID: 17695492]
200. Xiao YP, Wu DY, Xu L, Xin Y. Loss of heterozygosity and microsatellite instabilities of fragile histidine triad gene in gastric carcinoma. World J Gastroenterol 2006; 12: 3766-3769 [PMID: 16773697]
201. Zhang ZZ, Liu YJ, Yin XL, Zhan P, Gu Y, Ni XZ. Loss of BRCA1 expression leads to worse survival in patients with gastric carcinoma. World J Gastroenterol 2013; 19: 1968-1974 [PMID: 23569343 DOI: 10.3748/wjg.v19.i12.1968]
202. Chen W, Wang J, Li X, Li J, Zhou L, Qiu T, Zhang M, Liu P. Prognostic significance of BRCA1 expression in gastric cancer. Med Oncol 2013; 30: 423 [PMID: 23292835 DOI: 10.1007/s12032-012-0423-5]
203. Kim IJ, Park JH, Kang HC, Shin Y, Park HW, Park HR, Ku JL, Lim SB, Park JG. Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Hum Genet 2003; 114: 118-120 [PMID: 14513361 DOI: 10.1007/s00439-003-1027-0]
204. Warneke VS, Behrens HM, Haag J, Balschun K, Böger C, Becker T, Ebert MP, Lordick F, Röcken C. Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine. Diagn Mol Pathol 2013; 22: 127-137 [PMID: 23846438 DOI: 10.1097/PDM.0b013e318284188e]
205. Oh HS, Eom DW, Kang GH, Ahn YC, Lee SJ, Kim JH, Jang HJ, Kim EJ, Oh KH, Ahn HJ. Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection. Gastric Cancer 2014; 17: 402-411 [PMID: 23955257 DOI: 10.1007/s10120-013-0288-0]
206. Huang TJ, Wang JY, Lin SR, Lian ST, Hsieh JS. Overexpression of the c-met protooncogene in human gastric carcinoma - correlation to clinical features. Acta Oncol 2001; 40: 638-643 [PMID: 11669338]
207. Toyokawa T, Yashiro M, Hirakawa K. Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma. Oncol Rep 2009; 21: 875-880 [PMID: 19287982]
208. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 2005; 8: 86-94 [PMID: 15864715 DOI: 10.1007/s10120-005-0320-0]
209. Yamaguchi A, Goi T, Yu J, Hirono Y, Ishida M, Iida A, Kimura T, Takeuchi K, Katayama K, Hirose K. Expression of CD44v6 in advanced gastric cancer and its relationship to hematogenous metastasis and long-term prognosis. J Surg Oncol 2002; 79: 230-235 [PMID: 11920780 DOI: 10.1002/jso.10082]
210. Bessette DC, Qiu D, Pallen CJ. PRL PTPs: mediators and markers of cancer progression. Cancer Metastasis Rev 2008; 27: 231-252 [PMID: 18224294 DOI: 10.1007/s10555-008-9121-3]
211. Dai N, Lu AP, Shou CC, Li JY. Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer. World J Gastroenterol 2009; 15: 1499-1505 [PMID: 19322925]
212. Sanz-Ortega J, Steinberg SM, Moro E, Saez M, Lopez JA, Sierra E, Sanz-Esponera J, Merino MJ. Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer. Histol Histopathol 2000; 15: 455-462 [PMID: 10809364]
213. Han S, Kim HY, Park K, Cho HJ, Lee MS, Kim HJ, Kim YD. c-Myc expression is related with cell proliferation and associated with poor clinical outcome in human gastric cancer. J Korean Med Sci 1999; 14: 526-530 [PMID: 10576148]
214. Liu SZ, Zhang F, Chang YX, Ma J, Li X, Li XH, Fan JH, Duan GC, Sun XB. Prognostic impact of cyclin D1, cyclin E and P53 on gastroenteropancreatic neuroendocrine tumours. Asian Pac J Cancer Prev 2013; 14: 419-422 [PMID: 23534765]
215. Bernal C, Vargas M, Ossandón F, Santibáñez E, Urrutia J, Luengo V, Zavala LF, Backhouse C, Palma M, Argandoña J, Aguayo F, Corvalán A. DNA methylation profile in diffuse type gastric cancer: evidence for hypermethylation of the BRCA1 promoter region in early-onset gastric carcinogenesis. Biol Res 2008; 41: 303-315 [PMID: 19399343]
216. Leung WK, To KF, Chu ES, Chan MW, Bai AH, Ng EK, Chan FK, Sung JJ. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br J Cancer 2005; 92: 2190-2194 [PMID: 15942635 DOI: 10.1038/sj.bjc.6602636]
217. Graziano F, Arduini F, Ruzzo A, Bearzi I, Humar B, More H, Silva R, Muretto P, Guilford P, Testa E, Mari D, Magnani M, Cascinu S. Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, nodepositive, diffuse gastric cancer. Clin Cancer Res 2004; 10: 2784-2789 [PMID: 15102685]
218. Hu SL, Kong XY, Cheng ZD, Sun YB, Shen G, Xu WP, Wu L, Xu XC, Jiang XD, Huang DB. Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma. Tumori 2010; 96: 726-733 [PMID: 21302620]
219. Chen HY, Zhu BH, Zhang CH, Yang DJ, Peng JJ, Chen JH, Liu FK, He YL. High CpG island methylator phenotype is associated with lymph node metastasis and prognosis in gastric cancer. Cancer Sci 2012; 103: 73-79 [PMID: 22017425 DOI: 10.1111/j.1349-7006.2011.02129.x]
220. Hu SL, Huang DB, Sun YB, Wu L, Xu WP, Yin S, Chen J, Jiang XD, Shen G. Pathobiologic implications of methylation and expression status of Runx3 and CHFR genes in gastric cancer. Med Oncol 2011; 28: 447-454 [PMID: 20300977 DOI: 10.1007/s12032-010-9467-6]
221. Leung WK, Yu J, Ng EK, To KF, Ma PK, Lee TL, Go MY, Chung SC, Sung JJ. Concurrent hypermethylation of multiple tumor-related genes in gastric carcinoma and adjacent normal tissues. Cancer 2001; 91: 2294-2301 [PMID: 11413518]
222. Takada H, Imoto I, Tsuda H, Nakanishi Y, Ichikura T, Mochizuki H, Mitsufuji S, Hosoda F, Hirohashi S, Ohki M, Inazawa J. ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation. Oncogene 2005; 24: 8051-8060 [PMID: 16103878 DOI: 10.1038/sj.onc.1208952]
223. Watanabe Y, Kim HS, Castoro RJ, Chung W, Estecio MR, Kondo K, Guo Y, Ahmed SS, Toyota M, Itoh F, Suk KT, Cho MY, Shen L, Jelinek J, Issa JP. Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. Gastroenterology 2009; 136: 2149-2158 [PMID: 19375421 DOI: 10.1053/j.gastro.2009.02.085]
224. Shu XS, Geng H, Li L, Ying J, Ma C, Wang Y, Poon FF, Wang X, Ying Y, Yeo W, Srivastava G, Tsao SW, Yu J, Sung JJ, Huang S, Chan AT, Tao Q. The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/β-catenin signaling and is frequently silenced in multiple tumors. PLoS One 2011; 6: e27346 [PMID: 22087297 DOI: 10.1371/journal.pone.0027346]
225. Chang X, Li Z, Ma J, Deng P, Zhang S, Zhi Y, Chen J, Dai D. DNA methylation of NDRG2 in gastric cancer and its clinical significance. Dig Dis Sci 2013; 58: 715-723 [PMID: 23010743 DOI: 10.1007/s10620-012-2393-z]
226. Murai M, Toyota M, Suzuki H, Satoh A, Sasaki Y, Akino K, Ueno M, Takahashi F, Kusano M, Mita H, Yanagihara K, Endo T, Hinoda Y, Tokino T, Imai K. Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clin Cancer Res 2005; 11: 1021-1027 [PMID: 15709167]
227. Sugita H, Iida S, Inokuchi M, Kato K, Ishiguro M, Ishikawa T, Takagi Y, Enjoji M, Yamada H, Uetake H, Kojima K, Sugihara K. Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer. Oncol Rep 2011; 25: 513-518 [PMID: 21152877 DOI: 10.3892/or.2010.1085]
228. Kato K, Iida S, Uetake H, Takagi Y, Yamashita T, Inokuchi M, Yamada H, Kojima K, Sugihara K. Methylated TMS1 and DAPK genes predict prognosis and response to chemotherapy in gastric cancer. Int J Cancer 2008; 122: 603-608 [PMID: 17943730 DOI: 10.1002/ijc.23143]
229. Kang GH, Lee S, Kim WH, Lee HW, Kim JC, Rhyu MG, Ro JY. Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol 2002; 160: 787-794 [PMID: 11891177 DOI: 10.1016/s0002-9440(10)64901-2]
230. Wang S, Cheng Y, Du W, Lu L, Zhou L, Wang H, Kang W, Li X, Tao Q, Sung JJ, Yu J. Zinc-finger protein 545 is a novel tumour suppressor that acts by inhibiting ribosomal RNA transcription in gastric cancer. Gut 2013; 62: 833-841 [PMID: 22580414 DOI: 10.1136/gutjnl-2011-301776]
231. Kinoshita T, Nomoto S, Kodera Y, Koike M, Fujiwara M, Nakao A. Decreased expression and aberrant hypermethylation of the SFRP genes in human gastric cancer. Hepatogastroenterology 2011; 58: 1051-1056 [PMID: 21830441]
232. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, Yoshida K, Sasaki H, Nomura S, Seto Y, Kaminishi M, Calin GA, Croce CM. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010; 11: 136-146 [PMID: 20022810 DOI: 10.1016/s1470-2045(09)70343-2]
233. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, Huang D, Chen X, Zhang H, Zhuang R, Deng T, Liu H, Yin J, Wang S, Zen K, Ba Y, Zhang CY. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 2011; 47: 784-791 [PMID: 21112772 DOI: 10.1016/j.ejca.2010.10.025]
234. Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D, Xu L. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008; 8: 266 [PMID: 18803879 DOI: 10.1186/1471-2407-8-266]
235. Wan HY, Guo LM, Liu T, Liu M, Li X, Tang H. Regulation of the transcription factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. Mol Cancer 2010; 9: 16 [PMID: 20102618 DOI: 10.1186/1476-4598-9-16]
236. Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, Uchida T, Hijiya N, Matsuura K, Fujioka T, Seto M, Moriyama M. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res 2010; 70: 2339-2349 [PMID: 20215506 DOI: 10.1158/0008-5472.can-09-2777]